Protein 'Fingerprint' blood test could warn of ovarian cancer return

NCT ID NCT00086567

Completed Knowledge-focused Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 4 times

Summary

This study looks at proteins in the blood of women with ovarian, peritoneal, or fallopian tube cancer who are in remission. The goal is to find a protein pattern, or 'fingerprint,' that signals when the cancer might come back. Researchers followed 119 women with stage III or IV cancer for up to 4 years, taking blood samples and scans every few months. If a reliable fingerprint is found, it could lead to a simple blood test to catch relapses early.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could lead to a simple blood test that helps doctors predict when ovarian cancer might return, allowing for earlier intervention.
What could go wrong: This is an observational study, not a treatment trial. The protein fingerprint approach is still in early development and may not prove reliable enough for routine use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EPITHELIAL OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Carcinoma, Ovarian Epithelial fallopian tube cancer fallopian tube neoplasm ovarian carcinoma peritoneal neoplasm primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EPITHELIAL OVARIAN CANCER FALLOPIAN TUBE CANCER PERITONEAL NEOPLASMS

Contacts and locations

Show contact details

Locations

Cedars Sinai Medical Center

Los Angeles, California, 90048-1804, United States
Duke University Medical Center

Durham, North Carolina, 27710, United States
Evanston Northwestern University Hospital

Evanston, Illinois, United States
Fox Chase Cancer Center

Philadelphia, Pennsylvania, 19111, United States
Massachusetts General Hospital, Dana Farber

Boston, Massachusetts, 02114, United States
National Institutes of Health Clinical Center

Bethesda, Maryland, 20892, United States
New York University School of Medicine

New York, New York, 10016, United States
Pacific Ovarian Cancer Research Consortium at FHCRC

Seattle, Washington, United States
University of Alabama at Birmingham

Birmingham, Alabama, United States
University of Texas MD Anderson Cancer Center

Houston, Texas, 77030, United States
University of Washington/Fred Hutchinson Cancer Research Center

Seattle, Washington, 28104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.